The use of glucocorticoids in marmoset wasting syndrome

Pete Otovic1, Shanequa Smith2 & Eric Hutchinson1

1 Research Animal Resources, Johns Hopkins University, Baltimore, MD, USA
2 Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Keywords
Callitrichid – corticosteroids – inflammatory bowel disease – monkey

Abstract

Background Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation.

Method Eleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks.

Results The marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy.

Conclusions Glucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.

Introduction

Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets. Its prevalence has been reported to be as high as 60% in captive colonies [21], but these ranges may be misleading because one of the challenges surrounding MWS is that the same label has been applied inconsistently and to a dizzying array of disease processes. The only clinical sign consistently attributed to MWS is chronic weight loss, with concurrent alopecia and diarrhea also commonly reported, but paresis and paralysis have also been attributed to MWS (Table 1). Associated clinical pathology findings have included increases in calprotectin and decreases in hematocrit, whereas others have failed to find such changes and instead revealed decreases in albumin (Table 1). Histologically, many report a lymphoplasmacytic infiltration of the intestines, but even here, there is disagreement, with at least one report finding that neutrophils are the predominant white blood cell in the intestines.

While multiple groups have proposed etiologies and targeted therapies, no consensus has emerged in the literature. Gluten sensitivity is one proposed cause, with provision of a gluten-free diet appearing to ameliorate gastrointestinal symptoms in some animals [18]. Even within this study, however, only a fraction of the animals with clinical symptoms of MWS demonstrated gluten sensitivity. MWS has also been linked to infestation with Trichospirura leptostoma, but these marmosets showed hindlimb paresis without a decrease in albumin or total protein, all of which contrast to most other published descriptions of MWS. In our colony and others [5, 20], marmoset wasting disease is associated with weight loss and low serum albumin. In fact, a serum albumin below 3.5 g/dl or a weight of <325 g has 92% sensitivity, 100% specificity, and 100% positive predictive value for postmortem lymphoplasmacytic inflammation in the small and/or large intestines in our animals [5]. Thus, body weight and serum albumin may serve as useful markers of disease progression. Further, with no consensus as to etiology or specific therapeutic...
target for MWS, treatment might best be directed at the common clinical and pathological symptoms upon which most descriptions agree, namely GI inflammation and weight loss.

Glucocorticoids are arguably the most effective treatment for inducing remission in humans with inflammatory bowel disease (ulcerative colitis and Crohn’s disease), with remission rates up to 89% [27]. While prednisone is one example of an effective glucocorticoid, there are several adverse side effects associated with its use [11]. In humans, one of the most common side effects associated with prednisone use is osteopenia [9]. This is especially problematic in marmosets affected with MWS in our colony, as marmosets with MWS are over seven times more likely to be concurrently afflicted with metabolic bone disease and corresponding loss of bone density [5], a finding that has been mirrored elsewhere [15]. Budesonide is a glucocorticoid with few reported side effects, which largely result from up to 90% of it being metabolized into inactive compounds by the liver before entering the systemic circulation [2]. In addition, budesonide has a 15–200 times greater affinity for glucocorticoid receptors than prednisolone. Thus, budesonide primarily exerts its actions in the GI tract by altering the production of IL-6, IL-1, NF-κB, and TNF-α [4].

This study aimed to examine the efficacy of glucocorticoid therapy and specifically budesonide on MWS and predicted that the anti-inflammatory effects of such therapy would reverse the weight loss and decreases in serum albumin levels seen in our animals with MWS.

### Materials and methods

#### Humane care guidelines

All experimental procedures were approved and overseen by the Institutional Animal Care and Use Committee of Johns Hopkins University. Strict adherence to the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health, the Animal Welfare Act by the United States Department of Agriculture, and the Weatherall report by the Medical Research Council was observed.
Study animals

As in [4, 5], all marmosets in this study were between the ages of 2 and 6 years of age and housed in family units, in pairs, or singly as part of a large breeding and experimental colony at Johns Hopkins University, an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited institution. Animals were permitted ad libitum access to water and were fed a complete and balanced diet consisting of a custom homogenized blend of Teklad 8794N New World Primate Diet (Harlan Laboratories, Indianapolis, IN, USA), Zupreem 9920 CS canned marmoset diet (Shawnee, KS, USA), and Bio-Serv Newberne Hayes Vitamin Mix (San Diego, CA, USA), supplemented with various fruits and yogurt. Environmental enrichment in the form of visual and auditory contact with conspecifics, complex environments, and manipulanda were provided to all marmosets. Experienced animal care technicians observed animals at least once daily and more often if necessitated by experimental or medical need. The Johns Hopkins University Research Animal Resources veterinarians diagnosed, treated, and/or managed any medical illness or injury in the marmosets, and if euthanasia due to disease was warranted, marmosets were euthanized with an intravenous overdose of Euthasol (Virbac Corporation, Fort Worth, TX, USA) under deep ketamine anesthesia.

Marmosets presenting for progressive weight loss, adult body weight of ≤325 g, alopecia, or diarrhea received a physical exam, complete blood count, and serum chemistry, and fecal flotation and cultures were performed. The blood was collected from the femoral vein using 25-gauge needles, stored in lithium heparin tubes, and analyzed using a Hemavet 950 hematology analyzer (Drew Scientific Inc, Oxford, CT, USA) and vetACE chemical analyzer (Alfa Wassermann, West Caldwell, NJ, USA). The fecal flotation was performed in house using zinc sulfate solution to detect the presence of parasites such as Giardia, Cryptosporidium, Toxoplasmosis, and nematodes. Fecal cultures were submitted to detect the presence of Klebsiella spp, EPEC, Campylobacter spp, Yersinia spp, and Shigella spp. Although we did not specifically rule out Trichosporon sp infestation in individual cases, the vast majority of animals from this long-standing colony receive complete necropsies upon euthanasia or death, and this parasite has never been found in our facilities.

Animals were included in this study if their body weight was ≤325 g and their serum albumin was ≤3.5 g/dl [5]. The body weight and albumin levels must have remained below their respective thresholds for at least two consecutive samples, drawn 2 weeks apart.

Budesonide therapy

Eleven animals met these inclusion criteria and were begun on glucocorticoid therapy. Prednisone was used as the initial treatment for four animals, starting at a once-daily oral dose of 1 mg/kg that was then adjusted according to response to therapy. All of these animals were subsequently switched to treatment with budesonide. The remaining seven animals received budesonide as their only therapy. Regardless of when budesonide therapy was begun, it was initiated at 0.5 mg per animal orally once per day for 8 weeks. If after the initial 8 weeks an animal had not responded to therapy (i.e., still met inclusion criteria), the dose was increased to 0.75 mg and the animal followed for an additional 8 weeks. The budesonide was compounded into a pina colada-flavored liquid suspension by Kaye’s Pharmacy (Baltimore, MD, USA). Serum albumin and body weight were measured every 2 weeks during treatment.

Statistical analysis

All analyses were performed with a two-tailed repeated measures t-test using the Stata statistical software (StataCorp LP, College Station, Texas USA) package. For each individual animal, a mean of all available weight and serum albumin values prior to treatment was used as the ‘baseline’ condition, and this was compared to a mean of all values collected during treatment, regardless of duration or drug sequence. A Bonferroni correction for multiple comparisons was applied to base criteria for significance of $P < 0.05$. An ABAB single-subject research design and graph were used to depict the results from one of the study marmosets that happened to relapse after the cessation of the first 8-week course of glucocorticoid therapy. These data do not lend itself to statistical analysis and instead are presented in graphical form for visual inspection. However, this design allows the replication of both control and treatment conditions and encourages multiple data points to be collected and interpreted within each condition without being obscured via summary statistics.

Results

The results of a repeated measures t-test revealed that marmosets in our colony had a higher mean weight (M = 318.03 g) during treatment with glucocorticoids than they did prior to treatment [M = 287.75 g, t(10) = 2.75, $P = 0.021$]. Concordantly, a repeated measures t-test substantiated that marmosets had a high albumin during glucocorticoid therapy (M = 3.86 g/dl) than they did before treatment was initiated [M = 2.80 g/dl, \(t\)]
(10) = 6.23, \( P = 0.0001 \). These results are depicted in Table 2.

The results from one marmoset using a single-subject (ABAB) design are depicted in Figs 1 and 2. The graphs reveal stable and substantial increases in albumin (Fig. 1) and body weight (Fig. 2) in response to glucocorticoid therapy and decreases in both parameters after the cessation of therapy.

Discussion

The results of this study suggest that oral glucocorticoid therapy ameliorates decreases in the two diagnostic parameters most closely associated with MWS, body weight, and serum albumin. The lymphoplasmacytic inflammation found in the intestines of our marmosets with MWS shares histological characteristics with inflammatory bowel disease of dogs, cats, and humans, where oral glucocorticoids, most often in the form of prednisone, are the first-line therapy in mild to moderate cases. Although some research suggests that prednisone is more effective for inducing remission than budesonide [27], the side effects of prednisone administration make this drug less ideal and can include polyuria, polydipsia, polyphagia, redistribution of fat, thinning of skin, osteopenia, increased susceptibility to infections, and hyperglycemia [11]. There is evidence that budesonide, a drug with fewer systemic affects due to high ‘first pass’ metabolism in the liver, is effective at inducing remission in humans with mild to moderate ulcerative colitis [16], microscopic colitis [22], and Crohn’s disease [27]. Further, budesonide has been observed to reduce disease activity indices or induce clinical improvement and has been observed in dogs with signs of gastrointestinal inflammation [13, 24], in murine experimental models of colitis [1], and anecdotally in cats with inflammatory bowel disease [30].

Unlike prednisone, which has fairly well-established dosing guidelines, there is no established dosing guide for budesonide therapy in any animal species, and dose-dependent efficacy varies greatly. For instance, humans with IBD have needed anywhere from 3 to 18 mg per day [2], while dogs have been given doses from 1 to 9 mg per day [13, 24], and mice have been administered doses ranging from 0.168 to 0.5 mg/kg [1, 26]. While feline doses have not been published in the literature, clinical guidelines suggest doses of 1–2 mg per animal daily [30]. It is worth noting that in mice, it has been demonstrated that higher doses are not necessarily more effective, but are more likely to cause adverse side effects [1, 26]. Moreover, humans are more likely to respond to treatment with a higher concentration once per day than they are to the same dose split and given every 12 hours [8]. Thus, it is plausible that marmosets would also follow these trends. While our dosing of 0.5 mg per animal was somewhat arbitrary, this dose was based upon per animal clinical dosing guidelines used in cats and dogs.

While budesonide is a relatively effective drug for inducing remission in humans with IBD, neither it nor prednisone is very effective at maintaining remission [2, 27, 29]. Azathioprine, 6-MP, and methotrexate are used to maintain remission in Crohn’s disease, and any of these drugs or aminosalicylates are effective at maintaining remission in ulcerative colitis [29]. The relapse rate for patients treated with budesonide therapy has been reported to be as high as 67% [14]. Thus far we have had one marmoset relapse approximately 2 months after the cessation of budesonide therapy. This animal

| Animal | Mean weight (g) | Mean albumin (mg/dl) |
|--------|----------------|---------------------|
| A      | Pre-treatment  | During treatment    |
| B      | 255            | 346                 |
| C      | 293            | 321                 |
| D      | 253            | 310                 |
| E      | 249            | 304                 |
| F      | 288            | 308                 |
| G      | 318            | 277                 |
| H      | 335            | 340                 |
| I      | 300            | 324                 |
| J      | 290            | 281                 |
| K      | 273            | 317                 |
| Group means | 288 | 318             |

All weights are in grams and albumin is in milligrams per deciliter. SE, standard error.
responded well to a second 8-week course and is currently being maintained on 0.125 mg per day with no adverse consequences (Figs 1 and 2). Of 11 marmosets that have been treated, six have ceased therapy (some for as long as 6 months) and continue to thrive.

Although this study demonstrates the usefulness of budesonide as therapy for animals with chronic MWS, our clinical experience using budesonide for animals with more acute forms of GI illness has failed to produce similar results. In three cases, we initiated budesonide therapy to animals showing acute signs of gastrointestinal illness but not meeting the criteria for inclusion in this experiment. These three animals all died within a week of presentation despite budesonide therapy. However, remission rates and/or clinical improvement resulting from budesonide treatment can be as low as 18% in humans while still being more effective than placebo or other drugs. Moreover, budesonide is typically only indicated for mild to moderate forms of IBD in humans and thus is unlikely to be successful in the acute management of end stage disease [2, 25]. Other forms of therapy, which include TNF-\(\alpha\) inhibitors, intravenous methylprednisolone, and cyclosporine, are more appropriate for refractory or severe IBD in humans and might be useful in such acute marmoset cases [12, 29]. However, TNF-\(\alpha\) inhibitors may be cost prohibitive, limiting their availability in most vivaria.

It is possible that budesonide treatment increased weight and albumin via mechanisms other than by reducing gastrointestinal inflammation. For instance, it is possible that the budesonide worked by simply increasing appetite as is seen with prednisone administration. While we cannot definitively rule this out, this is
not a common side effect of budesonide in humans or dogs [11, 13]. Another possibility is that the animals included in this study would have improved regardless of budesonide therapy. However, this is not likely because MWS is known as a uniformly progressive disease without treatment, and these animals met previously established diagnostic criteria for MWS [5]. Additionally, in the one animal that was observed to relapse after the cessation of budesonide therapy, reinstitution of budesonide treatment again reversed this animal’s decline.

In conclusion, glucocorticoid therapy has demonstrated substantial potential to ameliorate clinical signs of MWS in our colony. Further, budesonide is an effective choice of glucocorticoid and is preferable to prednisone because of its decreased risk of side effects. Future experiments could be aimed at refining dosage requirements or comparing budesonide to other anti-inflammatory treatments such as TNF-α inhibitors or mesalazine.

Acknowledgments

We are indebted to the following individuals for their assistance with data collection and monitoring of the animals: Caroline Garrett, Theresa Meade, Rachael Cohen, Meghan Vermillion, Jessica Izzzi, and Cassie Moats. Thanks to Xiaojin Wang and his laboratory for permitting us to use his marmoset colony for this project.

References

1 Ali H, Weigmann B, Neurath MF, Collnot EM, Windbergs M, Lehr CM: Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release 2014; 183:167–77.
2 Angelucci E, Malesci A, Danese S: Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Curr Med Chem 2008; 15:2527–35.
3 Barnard D, Knapka J, Renquist D: The apparent reversal of a wasting syndrome by nutritional intervention in Saguinus-Mystax. Lab Anim Sci 1988; 38:282–8.
4 Barnes PJ: Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005; 25:451–68.
5 Baxter VK, Shaw GC, Sotuyo NP, Carlson CS, Olson EJ, Zink MC, Mankowski JL, Adams RJ, Hutchinson EK, Pate KAM: Serum albumin and body weight as biomarkers for the antemortem identification of bone and gastrointestinal disease in the common marmoset. PLoS One 2013; 8:e82747.
6 Beglinger R, Iilgen B, Pfister R, Heider K: The parasite Trichosporura leptostoma associated with wasting disease in a colony of common marmosets, Callithrix jacchus. Folia Primatol (Basel) 1988; 51:45–51.
7 Brack M, Rothe H: Chronic tubulointerstitial nephritis and wasting disease in marmosets (Callithrix jacchus). Vet Pathol 1981; 18:45–54.
8 Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG, Malchow H, Prantera C, Mani V, OMorain C, Selby W, Pullone F, d’Pietralata MM, Sjodahl R, Florin T, Smith P, Bianchi P, Lofergberg R, Rutgeerts P, Smallwood R, Lamers HW, Tasmajan C, Hunter JO, Hodgson H, Danielsson A, Lee FI, Piccielli G, Giovanni S, Ellis A, Weir DG: Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut 1997; 41:209–14.
9 Canalis E, Mazzioiti G, Giustina A, Bilezikian JP: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18:1319–28.
10 Chalifoux LV, Bronson RT, Escajidlo A, McKenna S: An analysis of the association of gastroenteric lesions with chronic wasting syndrome of marmosets. Vet Pathol 1982; 19:141–162.
11 Curkovic I, Egbring M, Kullak-UBlick GA: Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Dig Dis 2013; 31:68–73.
12 Danese S, Peyrin-Biroulet L: IBD IN 2013 enriching the therapeutic armamentarium for IBD. Nat Rev Gastroenterol Hepatol 2014; 11:84–5.
13 Dye TL, Diehl KJ, Wheeler SL, Westfall DS: Randomized, controlled trial of budesonide and prednisone for the treatment of idiopathic inflammatory bowel disease in dogs. J Vet Intern Med 2013; 27:1385–91.
14 Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, Rasenack J, Weber A, Gierend M, Ewe K, Scholmerich J, Grp BS: Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. Gut 1998; 42:493–6.
15 Jarcho MR, Power ML, Layne-Colon DG, Tardif SD: Digestive efficiency mediated by serum calcium predicts bone mineral density in the common marmoset (Callithrix jacchus). Am J Primatol 2013; 75:153–60.
16 Keller R, Stoll R, Foerster EC, Gutsche N, Domschke W: Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.
17 King G: An investigation into Wasting Marmoset Syndrome at Jersey Zoo. *Ann Rp, Jersey Wildl Preserv Trust* 1976; 97–107.

18 Kuehnel F, Mietsch M, Buettner T, Vervuert I, Ababneh R, Einspanier A: The influence of gluten on clinical and immunological status of common marmosets (*Callithrix jaccus*). *J Med Primatol* 2013; 42:300–9.

19 Lewis DH, Stein FJ, Sis RF, Mcmurray DN: Fecal microflora of marmosets with wasting marmoset syndrome. *Lab Anim Sci* 1987; 37:103–5.

20 Logan AC, Khan KNM: Clinical pathologic changes in two marmosets with wasting syndrome. *Toxicol Pathol* 1996; 24:707–9.

21 Ludlage E, Mansfield K: Clinical care and diseases of the common marmoset (*Callithrix jaccus*). *Comp Med* 2003; 53:369–82.

22 Mielhke S, Madisch A, Kupcinskas L, Petrauskas D, Bohm G, Marks HJ, Neumeyer M, Nathan T, Fernandez-Banares F, Greinwald R, Mohrbacher R, Vieth M, Bonderup OK, Grp B-CS: Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. *Gastroenterology* 2014; 146:1222–30.

23 Nakashima E, Okano Y, Niimi K, Takahashi E: Detection of calprotectin and apoptotic activity in the colon of marmosets with chronic diarrhea. *J Vet Med Sci* 2013; 75:1633–6.

24 Pietra M, Fracassi F, Diana A, Gazzotti T, Bettini G, Peli A, Morini M, Pagliuca G, Roncada P: Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. *Am J Vet Res* 2013; 74:78–83.

25 Sandborn WJ, Travis S, Moro L, Jones R, Gaullite T, Bagin R, Huang M, Yeung P, Ballard ED: Once-daily budesonide MMX (R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. *Gastroenterology* 2012; 143:1218–26.

26 Sann H, Erichsen J, Hessmann M, Pahl A, Hoffmeyer A: Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice. *Life Sci* 2013; 92:708–18.

27 Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH: Budesonide for induction of remission in Crohn’s disease. *Cochrane Database Syst Rev* 2008; 8:CD002913.

28 Shimwell M, Warrington BF, Fowler JSL: Dietary habits relating to wasting marmoset syndrome (Wms). *Lab Anim* 1979; 13:139–42.

29 Silverman J, Otley A: Budesonide in the treatment of inflammatory bowel disease. *Expert Rev Clin Immunol* 2011; 7:419–28.

30 Willard M: Canine and Feline Diarrheas: Diagnosis/Management of Infiltrative Disorders. ACVIM forum proceedings, June 3-6, 2009, Montreal, Quebec, Canada.